GuruFocus Premium Membership

Serving Intelligent Investors since 2004. Only 96 cents a day.

Free Trial

Free 7-day Trial
All Articles and Columns »

Yes, My Top Position Belongs to the '10 Times Revenue Club,' But It Is Not Facebook

February 14, 2012 | About:
As my beloved readers know well, I have a "value soul" but it is not rare to find in my portfolio a good number of "growth-y" stocks, whose valuation are, well, anything but cheap.

One of those stocks is Intuitive Surgical Inc. (ISRG) and it is now my first position (less than 15%). The "10 times revenue club" I mention in the title is a reference (maybe, a tribute) to a great post written by William Gurley, general partner at Benchmark Capital, where he warns of the risk of re-playing the mentality in vogue during the 'dot-com' bubble in the late '90s: "...Calculating or qualifying potential valuation using the simplistic and crude tool of a revenue multiple (also known as the price/revenue or price/sales ratio) was quite trendy back during the Internet bubble of the late 1990s. Perhaps it is not peculiar that our good friend the price/revenue ratio is back in vogue. But investors and analysts beware; this is a remarkably dangerous technique, because all revenues are not created equal."

Just to contextualize the numbers, I have listed below the average values (here I have used EV/sales in order to correct the numerator, P, or market cap, for the net cash or debt position of each company) for sectors (GICS) represented in the S&P 500:

Consumer Discretionary 1.7, Consumer Staples 1.8, Energy 2.9, Financials 5.0, Health Care 2.3, Industrials 1.6, Information Technology 2.7, Materials 1.8, Telecommunication Services 2.3, Utilities 2.2 --> average value S&P 500 = 2.6
So, 'our' ISRG, with its 9.7, is a stock with an EV/sales of 9.7, more than 4 times the average of its sector (health care) and one of the most expensive stock in the entire S&P 500.

But now, before talking about valuation and explaining why and if ISRG deserves this kind of valuation, I'll go straight on the recently published 10-K that covers the fiscal year ended Dec. 31, 2011, where I'll detail the most important lines in order to understand the business.

COMPANY BACKGROUND

"Intuitive designs, manufactures and markets da Vinci Surgical Systems and related instruments and accessories... This new generation of surgery, which we call da Vinci Surgery, combines the benefits of minimally invasive surgery (MIS) for patients with the ease of use, precision and dexterity of open surgery. A da Vinci Surgical System consists of a surgeon’s console, a patient-side cart and a high performance vision system. The da Vinci Surgical System translates a surgeon’s natural hand movements, which are performed on instrument controls at a console, into corresponding micro-movements of instruments positioned inside the patient through small incisions, or ports..."

This is the list with features and benefits they tell they provide to surgeons:

- Immersive 3-D Visualization;

- Intuitive Instrument Movements "...in conventional MIS, the instrument tip moves in the opposite direction from the surgeon’s hand and surgeons must adjust their hand-eye coordination to translate their hand movements in this “backward” environment;"

- EndoWrist Instruments;

- Scaled, Tremor Filtered Instrument Movement

- Improved Surgeon Ergonomics "...is designed to allow surgeons to operate while seated, which may be clinically advantageous because of reduced surgeon fatigue."
- Precise and Tremor-Free Endoscope Control;
PRODUCTS

da Vinci Surgical System:

- Surgeon’s Console;

- Patient-Side Cart;

- 3-D Vision System;

- Firefly Fluorescence Imaging;

- da Vinci Skills Simulator: "...the simulator is a practice tool which began shipping in early 2011 for the da Vinci Si Surgical System that gives a user the opportunity to practice his or her facility with the surgeon console controls." This is in my opinion a very interesting tool because it opens to a wider universe of surgeons the possibility to use this system so that hospitals can increase the number of procedures per system.
Instruments and Accessories

- EndoWrist Instruments;

- da Vinci Single-Site;

- EndoWrist One Vessel Sealer;

- Accessory Products.
BUSINESS STRATEGY

Patient Value = Efficacy/Invasiveness

Surgeon Value = Patient value + repeatable, teachable, and reliable

Hospital Value = Patient value + surgeon value + economic benefit
These three equations (taken from p. 5, ISRG's Q1 2012 presentation) actually explain well that by reducing the trauma --> narrowing recovering times --> this solution add value both to the patient (less pain) and to the hospital (less costs and less complications after surgery).

As a result, ISRG is now trying to expand its business by converting a significant percentage of older open procedures to da Vinci Surgery.

CLINICAL APPLICATIONS

ISRG is focused on five surgical specialties even if over 90% of the procedures performed were in the urologic and gynecologic specialties.

Below is the list of procedures:

- Urologic Surgery: Prostatectomy, Partial Nephrectomy, Pyeloplasty.

- Gynecologic Surgery: Hysterectomy, Myomectomy, Sacral Colpopexy, Endometriosis Resection.

- Cardiothoracic Surgery: Mitral Valve Repair, Thoracic Surgery.

- General Surgery: Colorectal Surgery, Gastric Bypass.

- Head and Neck Surgery: Transoral Surgery, Thyroidectomy.
CLINICAL SUMMARY

"As of December 31, 2011, we had an installed base of 2,132 da Vinci Surgical Systems. During the year ended December 31, 2011, we estimate that surgeons using our technology completed approximately 360,000 surgical procedures of various types in major hospitals throughout the world. Of those da Vinci procedures performed in 2011, we estimate that approximately 146,000 were da Vinci Hysterectomy (dVH) procedures and approximately 113,000 were da Vinci Prostatectomy (dVP) procedures." Just to give you an idea of the growth ahead, ISRG is estimating an addressable market of 2,000,000 procedures, of which, in U.S. only: Urology 150,000, Gynecology 500,000 (ISRG's Q1 2012 presentation, p. 17).

SALES AND CUSTOMER SUPPORT

"No one customer accounted for more than 10% of revenue during the years ended December 31, 2011, 2010 and 2009. As of December 31, 2011, we had approximately 790 employees in our field sales and service organizations..."

RESEARCH AND DEVELOPMENT

R&D expenses:

2011: $140.2 million

2010: $116.0 million

2009: $95.1 million
MANUFACTURING.

Sunnyvale, California and Mexicali, Mexico

COMPETITION

"Open surgery, conventional MIS in complex cases, drug therapies, radiation treatment and emerging interventional surgical approaches."

INTELLECTUAL PROPERTY AND GOVERNMENT REGULATION

These are in my opinion two of the reasons ISRG has an wide economic moat: (1) It has more than 1,000 patents that are behind its system, and (2) it is subject to regulation by FDA and other foreign body of international standards, so that a new entrant should not only spend a lot in R&D but it would have to wait (a long time) for accreditation.

THIRD-PARTY COVERAGE AND REIMBURSEMENT

Here reside one of the main risks. Whenever the procedures performed by hospitals and physicians are considered medically necessary, they are eligible for reimbursement from the government and insurance companies and so if there is more uncertainty relating to the amount reimbursed (particularly in this period of government budget constrains) this could represent a threat to ISRG's growth.

EMPLOYEES

1,924 employees

1,057 marketing, sales, and administrative activities

609 manufacturing and service

258 R&D
And now, finally, is the time to talk about numbers.



Revenue
201120102009


Instruments and accessories
$701.1$528.8$389.4


Systems
777.8660.3490.5


Total product revenue
1,478.91,189.1879.9


Services
278.4223.9172.3


Total revenue
$1,757.3$1,413.0$1,052.2


Recurring revenue
979.5752.7561.7


% of total revenue
56%53%53%


Revenue—Domestic
1,378.71,126.0827.0


Revenue—International
378.6287.0225.2


Total revenue
1,757.31,413.01,052.2
The revenue growth is impressive, around 30% YoY, and we have to consider the credit and the sovereign debt issues of the last years! But the very interesting fact is the recurring side of the revenue: looking at the higher growth from the recurring revenue, we can deduct that, at the limit, after establishing a da Vinci machine everywhere, what really will drive their future growth will be 'procedure growth'. In fact, converting a significant percentage of 'older' open procedures to da Vinci Surgery will mean that the customer is 'forced' to buy the instruments and accessories needed to perform a procedure --> the 'razor-blade' side of this razor-razor blade business model.

Now, how much am I going to pay to be a shareholder in this business (at a price of $510 and an EV of $18.8 billion as of Feb. 14, 2012)? These are the last cash flow numbers (from Morningstar):

2011-122010-122009-122008-122007-12
Operating cash flow678528385278206
Capital expenditure-83-96-53-106-24
Free cash flow595432332172182
Ocf (YoY Gr.)28,4%37,1%38,5%35,0%
Fcf (YoY Gr.)37,7%30,1%93,0%-5,5%


Well, exactly 30 times the last free cash flow number but for a growth of 30%.

Is this growth sustainable? Probably not, but for a wide-moat business that is establishing itself as a new standard for surgery I think that the probability it will be around in the next 10-20 years is high. As W. Buffett said in Berkshire Hathaway's 1999 meeting "...Our own emphasis is on trying to find businesses that are predictable in a general way as to where they'll be in 10 or 15 or 20 years. That means we look for businesses that in general aren't going to be susceptible to very much change. We view change as more of a threat investment-wise than an opportunity." In our case, the change is disruptive for the old procedure and seems to be good for Intuitive Surgical.

About the author:


Rating: 3.0/5 (14 votes)

Comments

Please leave your comment:


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide